Drug Development

The preclinical program to assess the pharmacological efficacy and potential toxicity of FE 203799 in-vitro and in-vivo is currently on-going. Submission of the dossier (IND/CTA) to the Regulatory Agencies before initiation of the clinical assays is aimed for Q1-2015.